NEW YORK (GenomeWeb) – Diagnostics startup IvyGene plans to launch a blood-based cancer detection test next month that relies on an epigenetic approach initially developed by researchers at the University of California San Diego.
A holding of a company called the Laboratory for Advanced Medicine, which has previously worked mainly with proteomic tests, IvyGene is launching the test this month through its CLIA lab, General Manager Nick Miner said in an interview.